{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=9", "query": { "intervention": "liposomal doxorubicin", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 1374, "total_pages": 138, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=liposomal+doxorubicin&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T07:37:46.358Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04032964", "title": "Dose Finding Study of L19TNF and Doxorubicin in Patients With STS", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "L19TNF", "type": "DRUG" }, { "name": "DOXORUBICIN", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Philogen S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 2, "start_date": "2019-09-05", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04032964" }, { "nct_id": "NCT00002878", "title": "Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "valspodar", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1997-06-30", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 32, "location_summary": "La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002878" }, { "nct_id": "NCT01387932", "title": "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "HepaSphere/QuadraSphere Microspheres", "type": "DEVICE" }, { "name": "PVA, lipiodol, doxorubicin", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Merit Medical Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2011-06", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387932" }, { "nct_id": "NCT01696032", "title": "SGI-110 in Combination With Carboplatin in Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "SGI-110", "type": "DRUG" }, { "name": "Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2012-09", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 13, "location_summary": "Los Angeles, California • Gainesville, Florida • Augusta, Georgia + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01696032" }, { "nct_id": "NCT00635193", "title": "Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer, Primary Peritoneal Cancer" ], "interventions": [ { "name": "M200 (Volociximab)", "type": "DRUG" }, { "name": "Liposomal Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 138, "start_date": "2007-07", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 14, "location_summary": "Anaheim, California • Redondo Beach, California • Sunrise, Florida + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Sunrise", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00635193" }, { "nct_id": "NCT01670084", "title": "Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Adult Acute Lymphoblastic Leukemia", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia", "Untreated Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "nilotinib", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2012-12", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2015-10-30", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01670084" }, { "nct_id": "NCT00002985", "title": "Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "1996-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002985" }, { "nct_id": "NCT04692155", "title": "Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ublituximab", "type": "DRUG" }, { "name": "Umbralisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-08-31", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692155" }, { "nct_id": "NCT03984448", "title": "Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Double-Expressor Lymphoma", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 363, "start_date": "2019-10-22", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 634, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984448" }, { "nct_id": "NCT00016406", "title": "S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 399, "start_date": "2001-05", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-14T07:37:46.358Z", "location_count": 314, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 204 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016406" } ] }